BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu JS, Wu DW, Liang S, Miao XY. GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol. 2010;27:339-345. [PMID: 19399652 DOI: 10.1007/s12032-009-9215-y] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Yao M, Yao DF, Bian YZ, Wu W, Yan XD, Yu DD, Qiu LW, Yang JL, Zhang HJ, Sai WL. Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2013;12:171-179. [PMID: 23558072 DOI: 10.1016/S1499-3872(13)60028-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
2 Zhu J, Warner E, Parikh ND, Lubman DM. Glycoproteomic markers of hepatocellular carcinoma-mass spectrometry based approaches. Mass Spectrom Rev 2019;38:265-90. [PMID: 30472795 DOI: 10.1002/mas.21583] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
3 Xia Y, Shen H, Zhu Y, Xu H, Li Z, Si J. A sensitive three monoclonal antibodies based automatic latex particle-enhanced turbidimetric immunoassay for Golgi protein 73 detection. Sci Rep 2017;7:40090. [PMID: 28054632 DOI: 10.1038/srep40090] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
4 Dai M, Chen X, Liu X, Peng Z, Meng J, Dai S. Diagnostic Value of the Combination of Golgi Protein 73 and Alpha-Fetoprotein in Hepatocellular Carcinoma: A Meta-Analysis. PLoS One. 2015;10:e0140067. [PMID: 26441340 DOI: 10.1371/journal.pone.0140067] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
5 Ibrahim GH, Mahmoud MA, Aly NM. Evaluation of circulating Transforming growth factor-beta1, Glypican-3 and Golgi protein-73 mRNAs expression as predictive markers for hepatocellular carcinoma in Egyptian patients. Mol Biol Rep. 2013;40:7069-7075. [PMID: 24186850 DOI: 10.1007/s11033-013-2829-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
6 Nascimento KP, Frizera-neto A, Marques C, Leal-junior AG. Machine learning techniques for liquid level estimation using FBG temperature sensor array. Optical Fiber Technology 2021;65:102612. [DOI: 10.1016/j.yofte.2021.102612] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
7 Zhou Z, Xia D, Wang C, Lin C, Zhao W, Dong C. Clinical evaluation of single or joint of golgi protein 73 and alpha-fetoprotein in hepatocellular carcinoma diagnosing. Chin -Ger J Clin Oncol 2012;11:650-4. [DOI: 10.1007/s10330-012-1072-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
8 Yuan Y, Shi L, Wang S. Expression and correlation of CD44 and GP73 in cerebroma tissues. Oncol Lett 2018;15:4958-62. [PMID: 29541250 DOI: 10.3892/ol.2018.7904] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Makhlouf MM, Mabood MA, Saleh SA, El Nakeep S, Abdelhakam SM, Rushdy M, Abd-al Hafez EM, Abbas A. Serum Golgi protein-73 in combination with α-fetoprotein for diagnosing hepatocellular carcinoma in Egyptian patients. Egypt J Intern Med 2017;29:40-6. [DOI: 10.4103/ejim.ejim_4_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Liu Y, Hu X, Liu S, Zhou S, Chen Z, Jin H. Golgi Phosphoprotein 73: The Driver of Epithelial-Mesenchymal Transition in Cancer. Front Oncol 2021;11:783860. [PMID: 34950590 DOI: 10.3389/fonc.2021.783860] [Reference Citation Analysis]
11 Mao R, Yang Y, Cao Q, Zhang RL, Zhang H, Xiao L, Bao YX. Significance of expression of Golgi glycoprotein 73 in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2014; 22(32): 4996-5000 [DOI: 10.11569/wcjd.v22.i32.4996] [Reference Citation Analysis]
12 Wang L, Yao M, Dong Z, Zhang Y, Yao D. Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring. Tumour Biol. 2014;35:9-20. [PMID: 24006223 DOI: 10.1007/s13277-013-1141-0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
13 Ai N, Liu W, Li ZG, Ji H, Li B, Yang G. High expression of GP73 in primary hepatocellular carcinoma and its function in the assessment of transcatheter arterial chemoembolization. Oncol Lett. 2017;14:3953-3958. [PMID: 28943903 DOI: 10.3892/ol.2017.6697] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
14 Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2015; 21(37): 10573-10583 [PMID: 26457017 DOI: 10.3748/wjg.v21.i37.10573] [Cited by in CrossRef: 188] [Cited by in F6Publishing: 182] [Article Influence: 26.9] [Reference Citation Analysis]
15 Liu X, Wan X, Lu S, Zhang L, Yu S, Lu X. Evaluation of a magnetic particles-based chemiluminescence enzyme immunoassay for Golgi protein 73 in human serum. Clin Chim Acta 2015;445:54-9. [PMID: 25801213 DOI: 10.1016/j.cca.2015.03.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
16 Yan J, Zhou B, Li H, Guo L, Ye Q. Recent advances of GOLM1 in hepatocellular carcinoma. Hepat Oncol 2020;7:HEP22. [PMID: 32647567 DOI: 10.2217/hep-2020-0006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Kim KH, Kim JY, Yoo JS. Mass spectrometry analysis of glycoprotein biomarkers in human blood of hepatocellular carcinoma. Expert Review of Proteomics 2019;16:553-68. [DOI: 10.1080/14789450.2019.1626235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhang J, Zhang M, Ma H, Song X, He L, Ye X, Li X. A meta-analysis of the prognostic significance of Golgi protein 73 in hepatocellular carcinoma in Chinese patients. Arch Med Sci 2020;16:1104-10. [PMID: 32863999 DOI: 10.5114/aoms.2019.83821] [Reference Citation Analysis]
19 Jin D, Tao J, Li D, Wang Y, Li L, Hu Z, Zhou Z, Chang X, Qu C, Zhang H. Golgi protein 73 activation of MMP-13 promotes hepatocellular carcinoma cell invasion. Oncotarget. 2015;6:33523-33533. [PMID: 26378022 DOI: 10.18632/oncotarget.5590] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
20 Li SQ, Chen Q. Advances in understanding the relationship between GP73 and hepatic diseases. Shijie Huaren Xiaohua Zazhi 2010; 18(20): 2117-2120 [DOI: 10.11569/wcjd.v18.i20.2117] [Reference Citation Analysis]
21 Shan SG, Gao YT, Xu YJ, Huang Y, Zhang Q, Zhai DK, Li JB, Wang FM, Jing X, Du Z, Wang YJ. Gradually increased Golgi protein 73 expression in the progression of benign liver diseases to precancerous lesions and hepatocellular carcinoma correlates with prognosis of patients. Hepatol Res. 2013;43:1199-1210. [PMID: 23607749 DOI: 10.1111/hepr.12078] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
22 Zhang YL, Zhang YC, Han W, Li YM, Wang GN, Yuan S, Wei FX, Wang JF, Jiang JJ, Zhang YW. Effect of GP73 silencing on proliferation and apoptosis in hepatocellular cancer. World J Gastroenterol 2014; 20(32): 11287-11296 [PMID: 25170213 DOI: 10.3748/wjg.v20.i32.11287] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
23 Chen LG, Wang HJ, Yao HB, Guan TP, Wu F, He XJ, Ma YY, Tao HQ, Ye ZY. GP73 is down-regulated in gastric cancer and associated with tumor differentiation. World J Surg Oncol 2013;11:132. [PMID: 23742050 DOI: 10.1186/1477-7819-11-132] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
24 Yang M, Guan Y, Yang Y, Xie L, Xia T, Xiong W, Guo C. Immunological detection of hepatocellular carcinoma biomarker GP73 based on dissolved magnetic nanoparticles. Colloids and Surfaces A: Physicochemical and Engineering Aspects 2014;443:280-5. [DOI: 10.1016/j.colsurfa.2013.11.026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
25 Farag RMA, Al Ayobi D, Alsaleh KA, Kwon HJ, EL-Ansary A, Dawoud EA. Studying the Impact of Golgi Protein 73 Serving as a Candidate Biomarker in Early Diagnosis for Hepatocellular Carcinoma among Saudi Patients. Asian Pac J Cancer Prev 2019;20:215-20. [PMID: 30678434 DOI: 10.31557/APJCP.2019.20.1.215] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
26 Wang L, Yao M, Liu S, Yang D, Wen X, Ning J, Wang L, Zhou G, Xu Q, Chen X, Zhao J, Lu F. Serum Golgi Protein 73 as a Potential Biomarker for Hepatic Necroinflammation in Population with Nonalcoholic Steatohepatitis. Dis Markers 2020;2020:6036904. [PMID: 32089754 DOI: 10.1155/2020/6036904] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Zhang J, Shao C, Zhou Q, Zhu Y, Zhu J, Tu C. Diagnostic accuracy of serum squamous cell carcinoma antigen and squamous cell carcinoma antigen-immunoglobulin M for hepatocellular carcinoma: A meta-analysis. Mol Clin Oncol. 2015;3:1165-1171. [PMID: 26623071 DOI: 10.3892/mco.2015.600] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
28 Li W, Wang X, Li B, Lu J, Chen G. Diagnostic Significance of Overexpression of Golgi Membrane Protein 1 in Prostate Cancer. Urology 2012;80:952.e1-7. [DOI: 10.1016/j.urology.2012.06.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
29 Hou SC, Xiao MB, Ni RZ, Ni WK, Jiang F, Li XY, Lu CH, Chen BY. Serum GP73 is complementary to AFP and GGT-II for the diagnosis of hepatocellular carcinoma. Oncol Lett 2013;6:1152-8. [PMID: 24137480 DOI: 10.3892/ol.2013.1522] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
30 Hann HW, Wang M, Hafner J, Long RE, Kim SH, Ahn M, Park S, Comunale MA, Block TM, Mehta A. Analysis of GP73 in patients with HCC as a function of anti-cancer treatment. Cancer Biomark 2010;7:269-73. [PMID: 21694465 DOI: 10.3233/CBM-2010-0190] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
31 Liu T, Yao M, Liu S, Wang L, Wang L, Hou J, Ma X, Jia J, Zhao J, Zhuang H, Lu F. Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. Oncotarget. 2017;8:16498-16506. [PMID: 28157705 DOI: 10.18632/oncotarget.14954] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
32 Zhou Y, Yin X, Ying J, Zhang B. Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer. 2012;12:17. [PMID: 22244200 DOI: 10.1186/1471-2407-12-17] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 5.6] [Reference Citation Analysis]
33 Lozada ME, Chaiteerakij R, Roberts LR. Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging? Curr Hepatol Rep 2015;14:128-38. [PMID: 26328266 DOI: 10.1007/s11901-015-0261-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
34 Wei H, Hao X, Li B, Li X, Hou J, Qiao Y, Zhang R. GP73 is a potential marker for evaluating AIDS progression and antiretroviral therapy efficacy. Mol Biol Rep. 2013;40:6397-6405. [PMID: 24068434 DOI: 10.1007/s11033-013-2754-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
35 Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, Shums Z, Aoki T, Hasegawa K, Beck Y, Sugawara Y, Kokudo N. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol. 2010;45:1272-1282. [PMID: 20625772 DOI: 10.1007/s00535-010-0278-5] [Cited by in Crossref: 106] [Cited by in F6Publishing: 98] [Article Influence: 8.8] [Reference Citation Analysis]
36 Liu W, Zhang A, Xu G, Wei F, Yang J, Hu Q. Manganese modified CdTe/CdS quantum dots as an immunoassay biosensor for the detection of Golgi protein-73. Journal of Pharmaceutical and Biomedical Analysis 2016;117:18-25. [DOI: 10.1016/j.jpba.2015.08.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
37 Zhou Y, Li L, Hu L, Peng T. Golgi phosphoprotein 2 (GOLPH2/GP73/GOLM1) interacts with secretory clusterin. Mol Biol Rep 2011;38:1457-62. [PMID: 20842452 DOI: 10.1007/s11033-010-0251-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
38 Zhang A, Cao B. Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA. J Biomed Res 2012;26:467-73. [PMID: 23554786 DOI: 10.7555/JBR.26.20120057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
39 Zhang J, Chen G, Zhang P, Zhang J, Li X, Gan D, Cao X, Han M, Du H, Ye Y. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One. 2020;15:e0228857. [PMID: 32053643 DOI: 10.1371/journal.pone.0228857] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 10.5] [Reference Citation Analysis]
40 Huang X, Liu F, Guan H, Jiang Z, Wei P, Luo Y, Jia Q. Effects of endoscopic submucosal dissection on post-operative early treatment effectiveness and serum TAT-2 and GP73 expression levels in patients with early gastric cancer. Exp Ther Med 2021;22:806. [PMID: 34093762 DOI: 10.3892/etm.2021.10238] [Reference Citation Analysis]
41 Mehta A, Herrera H, Block T. Glycosylation and liver cancer. Adv Cancer Res. 2015;126:257-279. [PMID: 25727150 DOI: 10.1016/bs.acr.2014.11.005] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 9.0] [Reference Citation Analysis]
42 Liang H, Block TM, Wang M, Nefsky B, Long R, Hafner J, Mehta AS, Marrero J, Gish R, Norton PA. Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. Cancer Biomark 2012;11:161-71. [PMID: 23144154 DOI: 10.3233/CBM-2012-00276] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
43 Yao M, Wang L, Leung PSC, Li Y, Liu S, Wang L, Guo X, Zhou G, Yan Y, Guan G, Chen X, Bowlus CL, Liu T, Jia J, Gershwin ME, Ma X, Zhao J, Lu F. The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. Clin Rev Allergy Immunol. 2018;54:282-294. [PMID: 29256057 DOI: 10.1007/s12016-017-8655-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
44 Li B, Li B, Guo T, Sun Z, Li X, Li X, Chen L, Zhao J, Mao Y. Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels of α-fetoprotein, α-fetoprotein-L3, des-γ-carboxy prothrombin, and Golgi protein 73. Oncotarget 2017;8:80521-30. [PMID: 29113322 DOI: 10.18632/oncotarget.19298] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
45 Chen CP, Haas-kogan D. Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics. Expert Review of Molecular Diagnostics 2014;10:883-95. [DOI: 10.1586/erm.10.76] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
46 Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Bröker ME, Ijzermans JN, Witjes CD, van Vuuren HJ, de Man RA. The predictive value of Golgi protein 73 in differentiating benign from malignant liver tumors. PLoS One 2014;9:e100187. [PMID: 25033446 DOI: 10.1371/journal.pone.0100187] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
48 Hu B, Tian X, Sun J, Meng X. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis. Int J Mol Sci. 2013;14:23559-23580. [PMID: 24317431 DOI: 10.3390/ijms141223559] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
49 Tian L, Wang Y, Xu D, Gui J, Jia X, Tong H, Wen X, Dong Z, Tian Y. Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int J Cancer. 2011;129:1923-1931. [PMID: 21140449 DOI: 10.1002/ijc.25838] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 5.1] [Reference Citation Analysis]
50 Xia Y, Zhang Y, Shen M, Xu H, Li Z, He N. Golgi protein 73 and its diagnostic value in liver diseases. Cell Prolif 2019;52:e12538. [PMID: 30341783 DOI: 10.1111/cpr.12538] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
51 Yang J, Li J, Dai W, Wang F, Shen M, Chen K, Cheng P, Zhang Y, Wang C, Zhu R. Golgi protein 73 as a biomarker for hepatocellular carcinoma: A diagnostic meta-analysis. Exp Ther Med. 2015;9:1413-1420. [PMID: 25780444 DOI: 10.3892/etm.2015.2231] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
52 Pandyarajan V, Govalan R, Yang JD. Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma. Int J Mol Sci 2021;22:E479. [PMID: 33418899 DOI: 10.3390/ijms22020479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]